Zai Lab Ltd
$ 19.03
4.56%
07 Jan - close price
- Market Cap 2,104,599,000 USD
- Current Price $ 19.03
- High / Low $ 19.32 / 18.81
- Stock P/E N/A
- Book Value 6.87
- EPS -1.90
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.29 %
- 52 Week High 44.34
- 52 Week Low 16.82
About
Zai Lab Limited (ZLAB), based in Shanghai, China, is a prominent biopharmaceutical company dedicated to the discovery, development, and commercialization of cutting-edge therapies targeting cancer, autoimmune diseases, and infectious diseases. With a robust pipeline of innovative drug candidates, Zai Lab strategically collaborates with global partners to meet critical unmet medical needs. As the biopharmaceutical landscape evolves, the company remains focused on improving patient outcomes through impactful research and development efforts, solidifying its role as a key player in the industry.
Analyst Target Price
$47.99
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-06 | 2025-02-25 | 2024-11-12 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-07 | 2023-08-07 | 2023-05-09 | 2023-03-01 |
| Reported EPS | -0.33 | -0.04 | -0.45 | -0.8 | -0.42 | -0.8 | -0.5 | -1 | -0.71 | -1.25 | -0.51 | -0.65 |
| Estimated EPS | -0.2453 | -0.41 | -0.5475 | -0.6333 | -0.78 | -0.71 | -0.92 | -0.86 | -1.04 | -0.79 | -0.95 | -1.11 |
| Surprise | -0.0847 | 0.37 | 0.0975 | -0.1667 | 0.36 | -0.09 | 0.42 | -0.14 | 0.33 | -0.46 | 0.44 | 0.46 |
| Surprise Percentage | -34.5291% | 90.2439% | 17.8082% | -26.3224% | 46.1538% | -12.6761% | 45.6522% | -16.2791% | 31.7308% | -58.2278% | 46.3158% | 41.4414% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.38 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZLAB
2026-01-08 14:33:02
UBS has initiated coverage on Zai Lab (ZLAB) with a 'Buy' rating and a price target of $35.00, signaling a positive outlook for the biopharmaceutical company. This follows consistently positive ratings from other analysts, with Citigroup and Leerink Partners raising their price targets in prior months. Wall Street analysts forecast an average price target of $47.35 for ZLAB, suggesting a significant upside from its current price.
2026-01-08 08:13:02
UBS has initiated coverage on Zai Lab (NASDAQ:ZLAB) with a Buy rating and a $35.00 price target, highlighting the company's shift from a China-focused model to a global innovation leader with a strong pipeline in oncology and immunology. Despite recent commercial setbacks in China and existing challenges like weak gross profit margins and negative earnings, UBS believes the stock is undervalued and poised for long-term growth. The investment bank emphasizes the potential of Zai Lab's global pipeline to diversify revenue and create significant shareholder value, suggesting an entry opportunity for investors given the stock's recent decline.
2026-01-08 01:13:02
Zai Lab's stock (ZLAB) rose 7.9% following China's approval of AUGTYRO (repotrectinib) for NTRK gene fusion solid tumors, including those previously treated with TRK TKIs. This makes AUGTYRO the first therapy in China approved for both TRK TKI-naive and pre-treated patients, strengthening Zai Lab's position in advanced oncology. The company's participation in the upcoming J.P. Morgan Healthcare Conference will provide an opportunity to discuss this expansion within its broader strategy.
2026-01-07 15:13:02
Zai Lab Limited (ZLAB) is highlighted as a compelling biotech investment with a $2 billion market cap, focusing on innovative treatments in various disease areas. Despite currently having negative earnings and free cash flow, the company shows promising revenue growth and strong analyst confidence with a 171% potential upside. Its strategic partnerships and diverse product pipeline in oncology and immunology position it for future growth, appealing to risk-tolerant, growth-oriented investors.
2026-01-07 11:10:35
Zai Lab has secured NMPA approval in China for its drug Augtyro (repotrectinib) to treat adult patients with NTRK gene fusion-positive solid tumors. This marks Augtyro's second indication in China, addressing a significant unmet medical need for patients who have progressed on prior therapies or lack satisfactory alternatives. The approval was based on results from the pivotal Phase I/II TRIDENT-1 study, which demonstrated the drug's durable efficacy and manageable safety profile.
2026-01-07 07:10:35
UBS initiated coverage on Zai Lab (NASDAQ:ZLAB) with a Buy rating and a $35 price target, citing the company's evolution from a China-focused model to a global innovation leader. Despite recent commercial setbacks and past earnings misses, UBS views Zai Lab as an undervalued biopharma platform with a strong global pipeline, offering significant long-term growth potential. The firm believes the market currently undervalues the company's strategic positioning and diversified revenue streams.
